FDA approves pediatric use of Dexcom’s G4 Platinum continuous glucose monitoring system – The U.S. Food and Drug Administration today approved the expanded use of the Dexcom G4 Platinum Continuous Monitoring System for patients with diabetes ages 2 to 17 years. The G4 Platinum System, which monitors blood glucose levels in people with diabetes, had been approved for patients ages 18 and older.
Treatment with antipsychotic drugs is associated with a significantly increased risk of hospitalization for hyperglycemia in old patients. – Older patients with diabetes who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, revealed by researchers.
Novo Nordisk Warns Customers About Stolen Insulin — FDA Issues Public Health Advisory Regarding Levemir Insulin. – Novo Nordisk product previously reported as stolen in North Carolina has resurfaced recently at a medical center in Houston.
Attorney General Martha Coakley and 32 Other Attorneys General Announce Record $62 Million Settlement with Drug Company – Eli Lilly and Company. – Attorney General Martha Coakley’s office, along with 32 other attorneys general, reached a record $62 million settlement with Eli Lilly and Company (Eli Lilly) resolving allegations of improper marketing of the atypical antipsychotic drug, Zyprexa.
A new testing device may give doctors early warning of eye disease, especially vision trouble linked to diabetes. – A new vision screening device, already shown to give an early warning of eye disease, could give doctors and patients a head start on treating diabetes and its vision complications, a new study shows.